Furthermore, this study revealed a notable reduction in HER2 mRNA stability in HR+/HER2-low breast cancer patients administered CDK 4/6 inhibitors, endocrine therapy, and neratinib three-agent regimens in comparison with CDK 4/6 inhibitors combined with endocrine therapy. This evidence concerns the gene ERBB2 and breast carcinoma.